Literature DB >> 30056945

Safety issues and recommendations for successful pregnancy outcome in systemic lupus erythematosus.

Simran Kaur Nahal1, Carlo Selmi2, M Eric Gershwin3.   

Abstract

Systemic lupus erythematosus (SLE) primarily affects women of childbearing age. One of the major changes in SLE focuses on the timing of a successful pregnancy. In the past, pregnancy was strongly discouraged in SLE, especially in the presence of risk factors such as nephritis, use of immunosuppressive therapies, or positivity of specific autoantibodies such as anti-phospholipids and anti-Ro/SSA, La/SSBA. Thanks to our better knowledge on the disease and management, pregnancy success rates in SLE patients have significantly improved care by the a multidisciplinary team which fosters a successful pregnancy with minimal complications for the mother and fetus when the disease is inactive or in remission. This approach is based on a counseling phase before pregnancy, to assess SLE activity phase, specific medications, risk factors, and continues through pregnancy and lactation with significantly improved pregnancy outcomes. Further, we can now better define the risk of disease flares during pregnancy based on a better understanding of the changes in maternal immunity and its relationship with SLE-associated autoimmunity and chronic inflammation. There is wide consensus that women with SLE can have successful pregnancies as long as conception is planned in a phase of inactive disease, and when the patient is closely managed by a rheumatologist, high-risk OB/GYN, neonatologist, and other medical specialists as indicated. Preconception counseling is essential to assess the risk of both fetal and maternal complications as well as identify life-threatening contraindications. Particular attention should be used in those SLE cases that have nephritis, APS or positivity for aPL, pulmonary hypertension, and positive anti-Ro/SSA or anti-La/SSB antibodies. In conclusion, the use of specific guidelines on the management of SLE before and during pregnancy and lactation, and a better understanding of the use of immunosuppressive therapies have significantly increased pregnancy success.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-phospholipid; Infertility; Miscarriage; Rheumatology; Teratogenicity

Mesh:

Substances:

Year:  2018        PMID: 30056945     DOI: 10.1016/j.jaut.2018.07.016

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  4 in total

Review 1.  Clinical features of new-onset systemic lupus erythematosus during pregnancy in Central China: a retrospective study of 68 pregnancies.

Authors:  Xiaodan He; Dongbin Jiang; Zhenbo Wang; Yao Li; Jingjing Wang; Dalin Xu; Jianqiang Chen; Xiaokang Liu; Guanmin Gao
Journal:  Clin Rheumatol       Date:  2020-10-16       Impact factor: 2.980

2.  A retrospective analysis of maternal complications and newborn outcomes of general anesthesia for cesarean delivery in a single tertiary hospital in China.

Authors:  Yang Bao; Ting Zhang; Ling Li; Changqing Zhou; Minxian Liang; Jie Zhou; Chunling Wang
Journal:  BMC Anesthesiol       Date:  2022-07-06       Impact factor: 2.376

3.  Characteristics of childhood-onset systemic lupus erythematosus in pregnancy and its association with pregnancy outcomes: a retrospective comparative cohort study.

Authors:  Zhi-Ju Li; Hao-Yue Hu; Zi-Ling Ding; Zi-Wei Bian; Ying-Hua Xu; Hui-Ting Wen; Ya-Li Qu; Jin-Dong Wang; Xiao-Li Huang; Dong Li; Jing Li; Gui-Fang Hu
Journal:  Reprod Biol Endocrinol       Date:  2022-05-19       Impact factor: 4.982

4.  Metabolic Biomarkers In Midtrimester Maternal Plasma Can Accurately Predict Adverse Pregnancy Outcome in Patients with SLE.

Authors:  Seung Mi Lee; Eun Mi Lee; Jin Kyun Park; Hae Sun Jeon; Sohee Oh; Subeen Hong; Young Mi Jung; Byoung Jae Kim; Sun Min Kim; Errol R Norwitz; Eun Bong Lee; Souphaphone Louangsenlath; Chan-Wook Park; Jong Kwan Jun; Joong Shin Park; Do Yup Lee
Journal:  Sci Rep       Date:  2019-10-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.